KiraGen Bio
KiraGen Bio is a biotechnology company focused on developing next-generation multiplex-edited cell therapies for solid and blood cancers. Their proprietary KiraLOGIC platform uses AI-guided combinatorial gene editing to reprogram immune cells, enabling them to evade tumor microenvironment suppression signals such as TGFβ and PD-1. This approach preserves immune cell potency and extends therapeutic responses, addressing the challenges of durable function in hostile tumor environments. KiraGen Bio's off-the-shelf donor-derived cell therapies aim to reduce costs and treatment timelines, expanding patient access. The company has gained recognition through multiple innovation competitions and partnerships, positioning itself as a pioneer in resilient CAR-T therapies for tough tumors.
KiraGen Bio
KiraGen Bio is a biotechnology company focused on developing next-generation multiplex-edited cell therapies for solid and blood cancers. Their proprietary KiraLOGIC platform uses AI-guided combinatorial gene editing to reprogram immune cells, enabling them to evade tumor microenvironment suppression signals such as TGFβ and PD-1. This approach preserves immune cell potency and extends therapeutic responses, addressing the challenges of durable function in hostile tumor environments. KiraGen Bio's off-the-shelf donor-derived cell therapies aim to reduce costs and treatment timelines, expanding patient access. The company has gained recognition through multiple innovation competitions and partnerships, positioning itself as a pioneer in resilient CAR-T therapies for tough tumors.
TL;DR
Founded: 2023
Headquarters: Allston, Massachusetts (127 Western Ave)
Focus: AI-driven multiplex gene-edited, off-the-shelf CAR-T cell therapies targeting tumor microenvironment suppression
Proprietary platform: KiraLOGIC (AI-guided combinatorial gene editing)
Notable validation: Selected for accelerator/competition cohorts (e.g., Recode Edge '25, LabCentral AI BioHub)
Company Overview
Problem Domain
Solid and blood cancers—overcoming tumor microenvironment–mediated suppression of cell therapies
Founded
2023
Industry
Biotechnology
Funding Track Record
Public profiles record one Pre-Seed round on this date and list multiple investors
Investor Signal
“Backed by early-stage investors including Pareto Holdings, Edward Lando, 2048 Ventures and ZAKA VC”